Novo Nordisk is rated a strong buy, offering a 4.2% dividend yield and trading at a 40% discount to its fair value. Although growth is currently pressured by U.S. price cuts and competition, the company is expected to achieve double-digit growth from 2027 onward due to volume increases and product expansion. Its Wegovy franchise, including a leading pill, is outperforming competitors internationally, with significant pipeline milestones anticipated in 2026–2027. Dividend growth is projected to average 7.5% through 2030, with an estimated total return CAGR of 18–23% over five years.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
